Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · CENTUPLE GLOBAL LIMITED · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
CENTUPLE GLOBAL LIMITED
BSE: 531099
BSE: 531099
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
CENTUPLE GLOBAL LIMITED
StateQ1 FY27 filed
Last close · 28 Oct 2026₹37.23
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA10.3 · 9.85 · 13.4
CENTUPLE GLOBAL LIMITED is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2 | 1 | 1 | 1 | 574 |
| EBITDA (ex other income) | (0) | (0) | 0 | 0 | 2 |
| margin % | (1.1) | (6.8) | 2.5 | 10.9 | 0.4 |
| Owners' profit | (0) | (0) | 0 | 0 | 2 |
| EPS, as reported (₹) | 0.00 | 0.00 | 0.06 | 0.05 | 5.52 |
| ROE % · ROCE % | (6.3) · (3.8) | (15.6) · (16.0) | 5.7 · 4.2 | 4.6 · 8.6 | 73.0 · 9.8 |
| Debt / equity (x) | 0.00 | 0.29 | 0.00 | 0.00 | 3.26 |
| Cash from operations | (0) | 0 | (0) | 0 | (28) |
| Capex | 0 | 0 | 0 | 0 | (0) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · CENTUPLE GLOBAL LIMITED · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 12 | 109 | 174 | 279 | 0 |
| Profit before tax | (0) | (0) | 0 | 0 | 2 | 1 | (0) | (0) |
| Net profit | (0) | (0) | 0 | 0 | 1 | 1 | (0) | (0) |
| EPS (₹) | (0.16) | (0.01) | 0.12 | 0.16 | 2.42 | 1.05 | 0.18 | (0.04) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Tobacco Products | 76 | 13.6 |
| FMCG Products | 486 | 86.4 |
| Total, before eliminations | 562 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 10.3 | 30.8 | 21 of 158 | 87% |
| P/B | 9.9 | 3.1 | 146 of 163 | 11% |
| ROCE | 9.8 | 10.8 | 101 of 183 | 45% |
| ROE | 73.0 | 9.8 | 2 of 166 | 99% |
| Debt / Equity | 3.3 | 0.2 | 165 of 166 | 1% |
| Revenue growth | (100.0) | 16.3 | 157 of 161 | 0% |
| Profit growth | (306.4) | 30.9 | 152 of 158 | 4% |
| Market cap | 20 | 806 | 165 of 181 | 9% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · CENTUPLE GLOBAL LIMITED · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 15 Oct 2026 · Postal Ballot notice published in newspapers | compliance | minimal | — | — |
| 13 Oct 2026 · Postal Ballot: Auditor appointment and director designation change | board shareholder meetings | low | — | — |
| 12 Oct 2026 · Board approves new Statutory Auditor and Whole-time Director designation change | management changes | medium | — | — |
| 8 Oct 2026 · Board meeting on Oct 12, 2026 to appoint statutory auditor and change director designation | management changes | medium | — | — |
| 6 Oct 2026 · Compliance certificate for dematerialisation of shares, Sep 2026 quarter | compliance | minimal | — | — |
| 1 Oct 2026 · Scrutinizer Report for 35th AGM filed - all resolutions passed | compliance | minimal | — | — |
| 1 Oct 2026 · AGM outcome: Both resolutions passed with 100% approval | board shareholder meetings | low | — | — |
| 30 Sept 2026 · 35th AGM held via video conferencing; financial statements adopted, new director appointed | board shareholder meetings | medium | — | — |
| 22 Sept 2026 · Board to consider Whole-Time Director appointment on Sept 24 | management changes | medium | — | — |
| 21 Sept 2026 · Trading window closes from Oct 1 for Q2 results declaration | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in